E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Transfusion-dependent beta thalassemia with myocardial iron overload |
|
E.1.1.1 | Medical condition in easily understood language |
Increased amount of iron in the heart muscle (iron overload) as a result of blood transfusions |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10005329 |
E.1.2 | Term | Blood and lymphatic system disorders |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Efficacy on cardiac iron as measured by cardiac T2* MRI in adult patients with transfusion-dependent beta thalassemia |
|
E.2.2 | Secondary objectives of the trial |
•Safety and tolerability in adult patients with transfusion-dependent beta thalassemia
•TSAT
•Immunogenicity (anti-LJPC-401 antibodies)
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacokinetic (PK) Sub-study
An optional PK substudy will be performed in a subset of subjects who provide a separate informed consent (approximately 20).
Blood sampling for PK will be taken at first dose at Hour -24, Hour 0, and post-dose Hours 0.5, 2, 4, 8, 12 (optional), 24, 48, and 168 (pre-dose before next weekly dosing). Hour 0 and Hour 168 can be combined with the immunogenicity and PK sample collected at Weeks 27 and 28 for Group A and Weeks 1 and 2 for Group B.
|
|
E.3 | Principal inclusion criteria |
1. Patients ≥ 18 years of age with transfusion-dependent beta thalassemia and must have been transfused within 1 month of randomization.
2. Patients must have a TSAT ≥ 50% at Screening.
3. Two separate cardiac MRIs should be greater than 3 weeks but no more than 3 months apart that both demonstrate cardiac T2* MRI of 6 to 35 (msec) with no more than a 10% difference between the first and second reading.
4. Patients must be receiving iron chelation therapy for a minimum of 1 year and be on a stable dose of maximally tolerated iron chelation therapy for a minimum of 8 weeks prior to study and expected to remain stable during study.
5. Female patients must be of non-childbearing potential, or using a highly effective method of contraception during participation in the study. Highly effective methods of contraception are defined as those, alone or in combination, that result in a low failure rate when used consistently and correctly. These include: surgical sterility (vasectomy, bilateral tubal ligation, or hysterectomy); hormonal intrauterine device (IUD); hormonal intrauterine system (IUS), implants, or injections; consistent use of an approved oral contraceptive pill (combined progestin/estrogen pill or progestin-only pill); combined intravaginal or transdermal method; and abstinence.
6. Female patients of childbearing potential must have a negative serum pregnancy test at Screening, and negative urine pregnancy test at Week 1 (ie, prior to initial dosing of study drug).
7. Male patients must be surgically sterile, or using a highly effective method of contraception during participation in the study. Highly effective methods of contraception are defined as those, alone or in combination, that result in a low failure rate when used consistently and correctly.
8. Patient must be willing and able to provide written informed consent. |
|
E.4 | Principal exclusion criteria |
1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating in the study.
2. Pregnant or lactating women.
3. Patients taking an immunosuppressive agent (excluding topical over-the-counter steroids) or have a planned surgery (excluding dental surgery or simple dermatologic procedures) during participation in this study or within 2 weeks prior to randomization.
4. Patients participating in an unapproved investigational drug or investigational therapeutic device study within 30 days prior to randomization, ie, there must be at least 30 days in between the last dose on a prior study and randomization on this trial.
5. Patients with a concomitant disease, disability or condition, including laboratory abnormality, which may interfere with the conduct of the study, or which would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study, including, but not limited to, alcohol dependency or abuse, drug dependency or abuse, or psychiatric disease.
6. Patients who are unwilling or unable to comply with the study protocol requirements.
7. Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.
8. Patients with Child Pugh class C cirrhosis or liver failure.
9. Patients with severe congestive heart failure (New York Heart Association [NYHA] = Class 4).
10. Use of erythropoiesis stimulating agents in the past 3 months prior to study entry.
11. History of allergic reaction to hepcidin or excipients.
12. Contraindication to MRI scanning. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The mean change from baseline (Screening) in intrapatient cardiac iron level as measured by T2* MRI at week 26 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Week 26 (comparing 26 weeks of Standard of Care (SOC) [Group A] to 26 weeks of SOC plus LJPC-401 [Group B]). |
|
E.5.2 | Secondary end point(s) |
1. Mean change from baseline (Screening) in intrapatient cardiac iron level as measured by cardiac T2* MRI at week 52
2. Mean change from baseline (Screening) in intrapatient cardiac iron level as measured by cardiac T2* MRI at post-baseline visits other than Week 26 and Week 52.
3. Change in time-weighted TSAT%.
4. The proportion of patients with an increase of at least 20% compared to baseline (Screening) in the T2* level as measured by cardiac MRI. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Week 52 (comparing delayed treatment/Group A [26 weeks of SOC followed by 26 weeks of SOC plus LJPC-401] to 52 weeks of immediate treatment/Group B [SOC + LJPC 401]) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Immediate treatment versus delayed treatment |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 18 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Cyprus |
Greece |
Italy |
Lebanon |
Thailand |
Turkey |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |